The number of cancer deaths worldwide has more than doubled since the 1980s. Does that mean we're losing the fight against cancer? Not necessarily, because it depends on how you measure it. On this chart, you can see three ways to look at the same data. ๐งต
A new tool from Rockefeller's @danmucida.bsky.social and @czbiohub.bsky.social allows scientists to closely follow newly activated T cells as they travel and change during an infectionโit may inform future therapies for infection, cancer, and autoimmunity.
๐: https://bit.ly/3NjZEWD
Thank you, Ariรซn!
@ostendorflab.org, @immushuang.bsky.social, @sohailtavazoie.bsky.social et al. show that activation of LXRs elicits a T cell "pre-effector" state that enhances priming and promotes anti-tumor immunity. rupress.org/jem/article/...
#TumorImmunology
thank you christian!
Huge thank you to all who contributed to this, particularly @sohailtavazoie.bsky.social , @immushuang.bsky.social, Bsky-less Jonathan Goldstein and all other co-authors. Also thank you to our funders, including @bihatcharite.bsky.social, Deutsche Krebshilfe, @dfg.de, DGIM and others.
Interestingly, we found that LXR activation induces a state in T cells that renders them more receptive to adopting effector states upon activation; this pre-conditioned state is quite fascinating and may be relevant beyond cancer.
Given their highly variable abundance, we now asked whether LXR agonism also works in tumors with low levels of g-MDSCs. This was indeed the case - and the effect was immune-mediated despite only very scarce g-MDSCs.
In Sohail's lab, we had previously found that LXR agonism enhances anti-tumor immunity by depleting granulocytic MDSCs.
Delighted to share our new paper on LXR agonism pre-conditioning T cells to more readily adopt effector states, out in @jem.org today. This was a long project started in @sohailtavazoie.bsky.social's lab and completed across the atlantic here in Berlin at Charitรฉ.
๐ฃ Weโre hiring! Pls share!
Join my lab to study human antigen-specific B cells across vaccination & infection backgrounds & explore their plasticity.
Passionate about B cells, cutting-edge immunology, molecular biology & bioinformatics?
๐Details & apply: karriere.charite.de/stellenangeb...
โณ Feb 28
โWe found that using AI assistance led to a statistically significant decrease in mastery.โ
Props to Anthropic for studying the effects of their creation and reporting results that are not probably what they wished for
www.anthropic.com/research/AI-...
A fascinating finding on the therapeutic potential of targeting non-coding regions of MYC!
New post!
There was a lot of innovation in medicine and biomedical research this year, and I've tried to summarize the biggest ones in this blogpost.
Medical breakthroughs in 2025. Plus a serious note at the end.
www.scientificdiscovery.dev/p/medical-br...
Completely agree! Now I mainly wish for Prism and Flowjo replacements...
Friday Papers Club! ๐ฟIn light of Pubmed going down, the collapse of social media, and my recent success at getting recommendations for interesting papers from those still around, I am starting a new tradition! - Recommend a good scientific manuscript! ๐
For our #flowcytometry peeps, would you like to have a single fix/perm protocol that is optimised for everything? One that preserves fluorophores while allowing simultaneous TF and cytokine staining? How about 100-fold cheaper?
You got it:
currentprotocols.onlinelibrary.wiley.com/doi/10.1002/...
Doomscrolling pause to chat CRISPR libraries! Preprint describes our new, data-driven approach to combine on-target and off-target predictions much more intelligently for *selecting* guides, which we use to develop our newest Cas9 knockout library, Jacquere. Thread: www.biorxiv.org/content/10.1...
Very interesting! The link leads to the ESPAC5 trial though, correct link here www.thelancet.com/journals/lan...
What a great thread on budgeting for an academic lab!!
๐งจExciting new pre-print ๐งจ Introducing ppmSeq - cost effective, scalable dual-strand ๐งฌ๐งฌ sequencing. Scalability & ultra-low error in one! A game changer for somatic genome discovery science and cfDNA clinical apps. Check out thread for deets!
Karolinska is looking for 20 (!!) assistant professors and offering 6 year appointments with ~1M USD startup packages.
ki.se/en/about-ki/...
It's my first #newPI roll call on BlueSky! Calling all new #cancer PIs who just started or who are about to start their labs! Please say hi and what you work on so I can follow you if I don't already! ๐
Different modes of resistance to RAS inhibitors unveiled by dual Erk reporters that monitor erk activity in the nucleus and the cytoplasm. Cool new paper led by Markus Morkel and Oleksandra Aust www.science.org/doi/10.1126/...
We're very happy to invite you to the ๐๐ซ๐ ๐๐จ๐ฎ๐ง๐ ๐๐๐ข๐๐ง๐ญ๐ข๐ฌ๐ญ ๐๐๐ง๐๐๐ซ ๐๐จ๐ง๐ ๐ซ๐๐ฌ๐ฌ ๐๐ญ ๐ญ๐ก๐ ๐
๐ซ๐๐ง๐๐ก ๐๐ฆ๐๐๐ฌ๐ฌ๐ฒ ๐ข๐ง ๐๐๐ซ๐ฅ๐ข๐ง ๐จ๐ง ๐๐๐ญ๐จ๐๐๐ซ ๐ &๐๐.
Visit our website ys2c.org for further information.
We have an attractive opening for a tenure-track professorship in Single-Cell Systems Biology. Excellent package and infrastructure at @uni-wuerzburg.de Institute of Systems Immunology. Great place to live and work in the heart of the franconian wine region!
jobs.sciencecareers.org/job/673667/j...
Presented at #ASCO25:
The addition of encorafenib and cetuximab to mFOLFOX6 chemotherapy improved outcomes in the primary treatment of metastatic BRAF V600Eโmutated colorectal cancer.
Full BREAKWATER phase 3 trial results:
Thanks so much, Veena ๐๐!
Excited to announce our preprint today @biorxivpreprint.bsky.social
Using functional genomics, we map the genetic determinants cancer cell sensitivity to tumour-reactive T cells:
www.biorxiv.org/content/10.1...
Thank you Yuko! ๐
